Physician profile
Emily Jester
NPI 1962177592
$2,629.86
in general payments reported to CMS, 2019-2025
31 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $264 · 2023: $873 · 2024: $1,112 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858 · Education: $393 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.13 |
| Education | $392.95 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $337.09 | 2023 | Xospata |
| Incyte Corporation | $322.08 | 2023-2025 | Niktimvo, Jakafi |
| Legend Biotech USA INC. | $241.31 | 2025 | Carvykti |
| Abbvie INC. | $188.74 | 2024 | |
| Rigel Pharmaceuticals, INC. | $176.94 | 2024 | Rezlidhia, Tavalisse |
| Sanofi-Aventis U.S. LLC | $139.50 | 2022 | |
| Genmab U.S., INC. | $118.06 | 2023-2024 | Epkinly |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Talvey |
| Lilly USA, LLC | $111.35 | 2022 | |
| Kite Pharma, INC. | $109.92 | 2023-2024 | Yescarta |
| Novartis Pharmaceuticals Corporation | $95.02 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $78.48 | 2023 | Monoferric |
| Tempus Ai, INC | $60.27 | 2024 | |
| Pfizer INC. | $54.14 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $52.07 | 2024 | Ultomiris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $49.53 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $42.92 | 2024 | Xpovio |
| Daiichi Sankyo INC. | $42.16 | 2024 | Vanflyta |
| Jazz Pharmaceuticals INC. | $40.42 | 2023-2024 | |
| Adc Therapeutics America, INC. | $39.61 | 2023 | |
| Janssen Biotech, INC. | $27.98 | 2023 | Tecvayli |
| Acrotech Biopharma INC. | $27.65 | 2023 | Beleodaq |
| Biolinerx USA, INC. | $22.14 | 2024 | Aphexda |
| Celgene Corporation | $21.36 | 2024 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $21.21 | 2023 | Epkinly |
| Seagen INC. | $18.70 | 2023 | Adcetris |
| Apellis Pharmaceuticals, INC. | $18.14 | 2023 | Empaveli |
| Cti Biopharma Corp. | $16.42 | 2023 | Vonjo |
| Beigene USA, INC. | $15.22 | 2023 | Brukinsa |
| Morphosys, US INC. | $13.50 | 2023 | Monjuvi |
| Amgen INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Jester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.